Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Jannsen Biotech extends its partnership with BTI on xB3!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Feb 02, 2023 6:45pm
136 Views
Post# 35263613

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Jannsen Biotech extends its partnership with BTI on xB3!!

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Jannsen Biotech extends its partnership with BTI on xB3!!
Unclepiecrusty says I have no impact. When I'm trying to understand something, when I spend time reading Bioasis and other documents, and I'm trying to understand what things mean, the last thing on my mind is impact, at least impact in some sort of self-aggrandizing way.
 
If you want to know what craving impact looks like, just recall the mindlessly repetitive posts from unclepiehole, fuzzykins and others, posts that have no other purpose than to damage and embarrass others. They've posted the same things over and over for years and years. 
 
They're craving impact, the same impact that spoiled brats try to get when they stamp their feet and cry because momma won't let them have the whole jar of cookies.
 
Whah whah whah whah...!!
 
jd
 
P.S. Today's word with impact comes from fuzzylogic - "skidmark"  - Let's hear it for fuzzybub!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities